A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: High rates of hepatitis C virus (HCV) transmission are found in samples of people who inject drugs (PWID) throughout the world. The objective of this paper was to meta-analyze the effects of risk-reduction interventions on HCV seroconversion and identify the most effective intervention types. METHODS: We performed a systematic review and meta-analysis of published and unpublished studies. Eligible studies reported on the association between participation in interventions intended to reduce unsafe drug injection and HCV seroconversion in samples of PWID. RESULTS: The meta-analysis included 26 eligible studies of behavioral interventions, substance-use treatment, syringe access, syringe disinfection, and multicomponent interventions. Interventions using multiple combined strategies reduced risk of seroconversion by 75% (pooled relative risk, .25; 95% confidence interval, .07-.83). Effects of single-method interventions ranged from .6 to 1.6. CONCLUSIONS: Interventions using strategies that combined substance-use treatment and support for safe injection were most effective at reducing HCV seroconversion. Determining the effective dose and combination of interventions for specific subgroups of PWID is a research priority. However, our meta-analysis shows that HCV infection can be prevented in PWID.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among individuals with OUDs, rates of HIV and viral hepatitis are substantially higher than in the general population, implying significantly higher costs to society for individuals with these co-occurring conditions (Hagan, Pouget, & Des Jarlais, 2011; Hess, Hu, Lansky, Mermin, & Hall, 2017).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Hagan, Pouget, & Des Jarlais, 2011
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
The New Zealand Medical Journal 1887-1987.
Rg, R. (1987) · PubMed · Cited by 3,673
QUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644 · cited 1×
“For 1 study [30] that reported only hazard ratios and P values, CIs were calculated using standard methods [31].”
MethodSharing of drug preparation equipment as a risk factor for hepatitis C
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.42 · Cited by 500 · cited 1×
“This finding is consistent with an understanding that an array of factors facilitate HCV transmission among PWID, including the large disease reservoir of HCV-infectious injectors, the efficiency with which HCV may be transmitted via a number of different drug injection–related practices, and the chaotic and rushed at…”
ResultSelf-citationThorpe, L. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.7.645 · Cited by 444
ON THE NEED FOR THE RARE DISEASE ASSUMPTION IN CASE-CONTROL STUDIES
GREENLAND, S., & THOMAS, D. C. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113439 · Cited by 442 · cited 2×
“Even adjusted RRs may not have been calculated following data-based approaches [59], and multivariate models may have included only statistically significant terms and thus omitted important confounding factors [29, 60].”
BackgroundMethodHepatitis C Virus Seroconversion among Young Injection Drug Users: Relationships and Risks
Hahn, J. A., Page‐Shafer, K., Lum, P. J., Bourgois, P., Stein, E., Evans, J. L., Busch, M. P., Tobler, L. H., Phelps, B., & Moss, A. R. (2002) · The Journal of Infectious Diseases · doi:10.1086/345554 · Cited by 326
Van Den Berg, C., Smit, C., Van Brussel, G., Coutinho, R., & Prins, M. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01912.x · Cited by 316
Gerberding, J. L. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.6.1410 · Cited by 304 · cited 2×
“HCV is highly efficiently transmitted via parenteral exposure to infectious blood, and the prevalence of HCV infection in PWID typically ranges between 40% and 90%, depending on geographic location and duration of exposure to injection drug use [1, 2].”
BackgroundSexual activity as a risk factor for hepatitis C
Terrault, N. A. (2002) · Hepatology · doi:10.1053/jhep.2002.36797 · Cited by 298
Is sexual contact a major mode of hepatitis C virus transmission?
Tohme, R. A., & Holmberg, S. D. (2010) · Hepatology · doi:10.1002/hep.23808 · Cited by 248 · cited 1×
“Given this and the much lower transmission efficiency via this route of exposure in other populations, prevention of sexual HCV transmission in PWID is currently of lesser importance, and thus this paper was restricted to prevention of injection-related transmission [26, 27].”
BackgroundPalmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., & Goldberg, D. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02888.x · Cited by 248 · cited 2×
“to identify any additional studies [22–25].”
ResultHagan, H., Jarlais, D. C., Friedman, S. R., Purchase, D., & Alter, M. J. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.11.1531 · Cited by 246
Self-citationDolan, K. A., Shearer, J., White, B., Zhou, J., Kaldor, J., & Wodak, A. D. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01050.x · Cited by 243
van Beek, I., Dwyer, R., Dore, G. J., Luo, K., & Kaldor, J. M. (1998) · BMJ · doi:10.1136/bmj.317.7156.433 · Cited by 234
Rhodes, T., Kimber, J., Small, W., Fitzgerald, J., Kerr, T., Hickman, M., & Holloway, G. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01556.x · Cited by 230
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia
Maher, L., Jalaludin, B., Chant, K. G., Jayasuriya, R., Sladden, T., Kaldor, J. M., & Sargent, P. L. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01543.x · Cited by 227 · cited 2×
“As shown in Table 2b, there was substantial heterogeneity in the association between participation in these programs and HCV seroconversion, with 2 studies showing lower rates of HCV infection among those exposed to drug treatment [8, 14] and 2 showing statistically significant higher rates [34, 36].”
BackgroundHagan, H., Pouget, E. R., Des Jarlais, D. C., & Lelutiu-Weinberger, C. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn237 · Cited by 222
Self-citationPatrick, D. M., TYNDALL, M. W., Cornelisse, P., Li, K. K., Sherlock, C. H., Rekart, M. L., Strathdee, S. A., Currie, S. L., Schechter, M. T., & O’Shaughnessy, M. V. (2001) · Europe PMC (PubMed Central) · Cited by 203
Schechter, M. T., Strathdee, S. A., Cornelisse, P. G. A., Currie, S., Patrick, D. M., Rekart, M. L., & O‚Shaughnessy, M. V. (1999) · AIDS · doi:10.1097/00002030-199904160-00002 · Cited by 172
Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion
Hagan, H., Thiede, H., & Des Jarlais, D. C. (2004) · Epidemiology · doi:10.1097/01.ede.0000135170.54913.9d · Cited by 170
Self-citationAn Improper Use of Statistical Significance Testing in Studying Covariables
DALES, L. G., & URY, H. K. (1978) · International Journal of Epidemiology · doi:10.1093/ije/7.4.373 · Cited by 169
Judd, A., Parry, J., Hickman, M., McDonald, T., Jordan, L., Lewis, K., Contreras, M., Dusheiko, G., Foster, G., Gill, N., et al. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10463 · Cited by 166 · cited 1×
“In addition, HCV status must have been determined by serologic testing of either sera or oral fluids; oral fluid tests have been shown to have high sensitivity (92%) and specificity (99%) [21].”
BackgroundGarfein, R. S., Golub, E. T., Greenberg, A. E., Hagan, H., Hanson, D. L., Hudson, S. M., Kapadia, F., Latka, M. H., Ouellet, L. J., Purcell, D. W., et al. (2007) · AIDS · doi:10.1097/qad.0b013e32823f9066 · Cited by 159
Self-citationRapid transmission of hepatitis C virus among young injecting heroin users in Southern China
Garten, R. J. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh019 · Cited by 159 · cited 1×
“However, incidence rates above and below this range have been recorded, with some of the highest rates observed in recent-onset drug injectors and in low- and middle-income countries [2, 11–14].”
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users
van den Berg, C. H. S. B., Smit, C., Bakker, M. E., Geskus, R. B., Berkhout, B., Jurriaans, S., Coutinho, R. A., Wolthers, K. C., & Prins, M. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-006-9089-7 · Cited by 138 · cited 1×
“Most reports of HCV incidence in PWID fall into the range of 20–40 infections per 100 PY [6–10].”
Attribution of Hepatitis C Virus Seroconversion Risk in Young Injection Drug Users in 5 US Cities
Hagan, H., Pouget, E. R., Williams, I. T., Garfein, R. L., Strathdee, S. A., Hudson, S. M., Latka, M. H., & Ouellet, L. J. (2010) · The Journal of Infectious Diseases · doi:10.1086/649783 · Cited by 125 · cited 1×
“This finding is consistent with an understanding that an array of factors facilitate HCV transmission among PWID, including the large disease reservoir of HCV-infectious injectors, the efficiency with which HCV may be transmitted via a number of different drug injection–related practices, and the chaotic and rushed at…”
ResultSelf-citationHigh hepatitis C incidence in new injecting drug users: a policy failure?
Maher, L., Li, J., Jalaludin, B. B., Chant, K. G., & Kaldor, J. M. (2007) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2007.00007.x · Cited by 122 · cited 1×
“However, incidence rates above and below this range have been recorded, with some of the highest rates observed in recent-onset drug injectors and in low- and middle-income countries [2, 11–14].”
Methadone maintenance and hepatitis C virus infection among injecting drug users
Crofts, N., Nigro, L., Oman, K., Stevenson, E., & Sherman, J. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.9289999.x · Cited by 117
Craine, N., Hickman, M., Parry, J., Smith, J., Walker, A., Russell, D., Nix, B., May, M., McDonald, T., & Lyons, M. (2009) · Epidemiology and Infection · doi:10.1017/s095026880900212x · Cited by 108
High hepatitis C virus prevalence and incidence among Canadian intravenous drug users
Roy, É., Alary, M., Morissette, C., Leclerc, P., Boudreau, J., Parent, R., Rochefort, J., Claessens, C., & The SurvUDI Working Group (2007) · International Journal of STD & AIDS · doi:10.1258/095646207779949880 · Cited by 92
High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan.
Kuo, I. C., Hasan, S. U., Galai, N., Thomas, D. L., Zafar, T., Ahmed, M., & Strathdee, S. A. (2006) · Harm Reduction Journal · doi:10.1186/1477-7517-3-26 · Cited by 91
The impact of injecting drug use status on hepatitis C-related referral and treatment
Stoove, M. A., Gifford, S., & Dore, G. J. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.07.002 · Cited by 91 · cited 1×
“Treatment for HCV infection is costly, and PWID are less likely to receive medical monitoring and treatment of the infection than other patient groups [17, 18].”
BackgroundIntranasal Transmission of Hepatitis C Virus: Virological and Clinical Evidence
Aaron, S., McMahon, J. M., Milano, D., Torres, L., Clatts, M. C., Tortu, S., Mildvan, D., & Simm, M. (2008) · Clinical Infectious Diseases · doi:10.1086/591699 · Cited by 90 · cited 1×
“drug users have been identified as having a biologically plausible risk of exposure to HCV infection via drug-use practices, either through percutaneous or mucous membrane exposure to blood via sharing of straws or through pipes used to administer drugs [1, 20].”
BackgroundMethadone treatment and hiv and hepatitis band C risk reduction among injectiors in the seattle area
Thiede, H., Hagan, H., & Murrill, C. S. (2000) · Journal of Urban Health · doi:10.1007/bf02386744 · Cited by 87
Self-citationHepatitis C virus evasion of adaptive immune responses: a model for viral persistence
Burke, K. P., & Cox, A. L. (2010) · Immunologic Research · doi:10.1007/s12026-009-8152-3 · Cited by 86 · cited 1×
“Acute HCV infection results in chronic carriage in 70%–80% of cases, and 20%–25% of those with persistent infection will develop liver disease that may manifest as cirrhosis, liver failure, or hepatocellular carcinoma [15].”
BackgroundOptimal provision of needle and syringe programmes for injecting drug users: A systematic review
Jones, L., Pickering, L., Sumnall, H. R., McVeigh, J., & Bellis, M. A. (2010) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2010.02.001 · Cited by 85 · cited 2×
“to identify any additional studies [22–25].”
ResultHoltzman, D. J., Barry, V., Ouellet, L. J., Jarlais, D. C. D., Vlahov, D., Golub, E. T., Hudson, S., & Garfein, R. S. (2009) · Preventive Medicine · doi:10.1016/j.ypmed.2009.04.014 · Cited by 81
A certain fate: Spread of HIV among young injecting drug users in Manipur, North-East India
Eicher, A. D., Crofts, N., Benjamin, S., Deutschmann, P. W., & Rodger, A. J. (2000) · AIDS Care · doi:10.1080/09540120050123891 · Cited by 81 · cited 1×
“Extremely high HCV prevalence rates—between 85% and 98%—have been reported [3–5].”
BackgroundLucidarme, D., Bruandet, A., Ilèf, D., Harbonnier, J., Jacob, C., Decoster, A., Delamare, C., Cyran, C., Hoenacker, A. F. V., Fremaux, D., et al. (2004) · Epidemiology and Infection · doi:10.1017/s095026880400247x · Cited by 80 · cited 17×
“In 1 early study, HCV incidence was higher among those who remained in ORT as compared with that among those who left or had no ORT during follow-up [38].”
ResultInfluentialRezza, G., Sagliocca, L., Zaccarell, M., Nespoli, M., Siconolfi, M., & Baldassarre, C. (1996) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549609027145 · Cited by 75
Wright, N. M. J., & Tompkins, C. N. E. (2006) · Harm Reduction Journal · doi:10.1186/1477-7517-3-27 · Cited by 62 · cited 2×
“to identify any additional studies [22–25].”
Resultvan de Laar, T. J. W., Langendam, M. W., Bruisten, S. M., Welp, E. A. E., Verhaest, I., van Ameijden, E. J. C., Coutinho, R. A., & Prins, M. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20486 · Cited by 54 · cited 2×
“A b o u -S a le h , 2 0 0 8 [5 2 ] L o n d o n a n d S u rr e y ,”
BackgroundVolunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs
Hagan, H., McGough, J. P., Thiede, H., Hopkins, S. G., Weiss, N. S., & Alexander, E. R. (2000) · Journal of Urban Health · doi:10.1007/bf02350966 · Cited by 50
Self-citationKapadia, F., Vlahov, D., Jarlais, D. C. D., Strathdee, S. A., Ouellet, L. J., Kerndt, P. R., Morse, E. V., Williams, I., & Garfein, R. S. (2002) · Epidemiology · doi:10.1097/00001648-200211000-00023 · Cited by 48
How can hepatitis C be prevented in the long term?
Mateu‐Gelabert, P., Treloar, C., Calatayud, V. A., Sandoval, M., Valderrama‐Zurián, J. C., Maher, L., Rhodes, T., & Friedman, S. R. (2007) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2007.06.001 · Cited by 44
Abou‐Saleh, M. T., Davis, P. W., Rice, P. S., Checinski, K., Drummond, C., Maxwell, D., Godfrey, C., John, C., Corrin, B., Tibbs, C., et al. (2008) · Harm Reduction Journal · doi:10.1186/1477-7517-5-25 · Cited by 42
Smyth, B. P., O’Connor, J. J., Barry, J., & Keenan, E. (2003) · Journal of Epidemiology and Community Health · doi:10.1136/jech.57.4.310 · Cited by 35 · cited 4×
“As shown in Table 2b, there was substantial heterogeneity in the association between participation in these programs and HCV seroconversion, with 2 studies showing lower rates of HCV infection among those exposed to drug treatment [8, 14] and 2 showing statistically significant higher rates [34, 36].”
BackgroundResultInfluentialThe HCV Synthesis Project: Scope, methodology, and preliminary results
Stern, R., Hagan, H., Lelutiu‐Weinberger, C., Jarlais, D. D., Scheinmann, R., Strauss, S. M., Pouget, E. R., & Flom, P. L. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-62 · Cited by 27
Self-citationCumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users.
Brunton, C. R., Kemp, R., Raynel, P. D., Harte, D., & Baker, M. (2000) · PubMed · Cited by 22
Does Bleach Disinfection of Syringes Help Prevent Hepatitis C Virus Transmission?
Hagan, H., & Thiede, H. (2003) · Epidemiology · doi:10.1097/01.ede.0000071484.08937.80 · Cited by 21
Self-citationHCV reinfection studies and the door to vaccine development
Grebely, J., Thomas, D. L., & Dore, G. J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.002 · Cited by 20 · cited 2×
“Treatment for HCV infection is costly, and PWID are less likely to receive medical monitoring and treatment of the infection than other patient groups [17, 18].”
BackgroundA Trial to Reduce Hepatitis C Seroincidence in Drug Users
Stein, M. D., Herman, D. S., & Anderson, B. J. (2009) · Journal of Addictive Diseases · doi:10.1080/10550880903183034 · Cited by 18 · cited 3×
“Stein, 2009 [33] Providence, RI, United States 2001–2004 RCT, Cohort N 5 89 15.”
BackgroundHepatitis C virus incidence among injecting drug users on opioid replacement therapy
Hallinan, R., Byrne, A., Amin, J., & Dore, G. J. (2004) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2004.tb00050.x · Cited by 18
Hallinan, R., BYRNE, A., & Dore, G. J. (2007) · Drug and Alcohol Review · doi:10.1080/09595230701373933 · Cited by 10
Deuffic‐Burban, S. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2010.09.004 · Cited by 4 · cited 1×
“In the United States, it is expected that HCV-related mortality will surpass HIV-related mortality in the coming years [16].”
BackgroundHagan, H., Pouget, E. R., & Garfein, R. S. (2010) · The Journal of Infectious Diseases · doi:10.1086/653841 · Cited by 1
Self-citation
Research works printed but not linked: 4
- Terrault, 2002, Hepatology (Baltimore, Md.), 36, S99, 10.1002/hep.1840360713 · doi:10.1002/hep.1840360713 · Paper page
- Brunton, 2000, The New Zealand medical journal, 113, 98
- Patrick, 2001, Canadian Medical Association Journal, 165, 889
- Crofts, 1997, Addiction (Abingdon, England), 92, 999, 10.1111/j.1360-0443.1997.tb02979.x · doi:10.1111/j.1360-0443.1997.tb02979.x · Paper page
Cited by
Suryaprasad, A. G., White, J. Z., Xu, F., Eichler, B.-A., Hamilton, J., Patel, A., Hamdounia, S. B., Church, D. R., Barton, K., Fisher, C., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu643 · Cited by 500
“shown to reduce HCV seroconversion by 75% [35].”
BackgroundMartin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Luchenski, S., Maguire, N., Aldridge, R. W., Hayward, A., Story, A., Perri, P., Withers, J., Clint, S., Fitzpatrick, S., & Hewett, N. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31959-1 · Cited by 430
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., et al. (2018) · Addiction · doi:10.1111/add.14012 · Cited by 362
Self-citationKoh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Metadata
- Authors
- Hagan, H., Pouget, E. R., & Des Jarlais, D. C.
- Affiliations
- New York University (US)
- National Development and Research Institutes (US)
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-31
- Volume
- 204
- Issue
- 1
- Pages
- 74-83
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC3105033
- OpenAlex
- W2110957526
- Cited by
- 313
- References
- 62
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 15 · 2021: 19 · 2020: 19 · 2019: 26 · 2018: 27 · 2017: 32 · 2016: 28 · 2015: 31 · 2014: 31 · 2013: 28 · 2012: 19
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA018609, P30 DA121041)
- Topics
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- hepatitis C virus, people who inject drugs, HCV seroconversion, harm reduction interventions, syringe access, addiction treatment, behavioral interventions, multicomponent intervention, injection safety
- MeSH terms
- Behavior Therapy, Communicable Disease Control, Hepatitis C, Humans, Substance Abuse, Intravenous, Treatment Outcome, Disease Transmission, Infectious
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.